Capital News

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s X-Linked Retinitis Pigmentosa (XLRP) Market Insights, Epidemiology, and Market Forecast – 2036.” This comprehensive report provides an in-depth understanding of X-Linked Retinitis Pigmentosa (XLRP), including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the X-Linked Retinitis Pigmentosa (XLRP) Market

• The market size for X-Linked Retinitis Pigmentosa (XLRP) in the leading markets is expected to grow significantly by 2036.

• The United States accounted for the highest X-Linked Retinitis Pigmentosa (XLRP) treatment market size in the 7MM in 2025, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.

• DelveInsight’s analysis estimates that the X-Linked Retinitis Pigmentosa (XLRP) market is expected to increase from approximately USD 500 million in 2022 to nearly USD 800 million by 2036, driven by the anticipated launch of novel gene therapies and increasing diagnosis of inherited retinal diseases.

• According to the study by Pungor et al. (2024), retinitis pigmentosa has a prevalence of approximately 1 in 3,500–4,000 individuals, with 10–15% of patients having X-Linked Retinitis Pigmentosa, one of the most progressive forms of retinitis pigmentosa.

• According to Simpson et al. (2022), the prevalence of X-Linked Retinitis Pigmentosa is estimated to be 2.7–3.5 per 100,000 males in the United States and Europe, while RPGR-mutated XLRP accounts for approximately 3.4–4.4 per 100,000 males.

• According to NORD (2021), retinitis pigmentosa affects approximately 1 in 3,000–4,000 people worldwide, representing nearly 82,000–109,000 individuals in the United States.

• In 2025, the total prevalent cases of retinitis pigmentosa were nearly 276,000 across the 7MM, of which approximately 16,700 represented X-Linked Retinitis Pigmentosa. The United States accounted for nearly 11,200 XLRP cases, while Japan reported the lowest burden with nearly 550 cases.

• Approximately 70–80% of patients with RPGR-associated XLRP possess pathogenic variants involving RPGR exons 1–14 and the ORF15 region, making RPGR the primary therapeutic target for emerging gene therapies.

• Leading X-Linked Retinitis Pigmentosa companies, such as Beacon Therapeutics, Johnson & Johnson Innovative Medicine, MeiraGTx, Frontera Therapeutics, and others, are developing innovative gene therapies expected to transform the XLRP treatment landscape.

• The promising X-Linked Retinitis Pigmentosa therapies in clinical development include Laru-Zova, Botaretigene sparoparvovec (bota-vec), FT-002, and others.

Keen to know more about the market? Request our sample page at https://www.delveinsight.com/sample-request/x-linked-retinitis-pigmentosa-market

Key Factors Driving the X-Linked Retinitis Pigmentosa (XLRP) Market

Increasing Adoption of Genetic Testing and Earlier Diagnosis: Advances in molecular diagnostics and wider availability of genetic testing have significantly improved the identification of RPGR mutations, enabling earlier diagnosis and patient selection for emerging gene therapies.

Rapid Advancement of Gene Therapy Technologies: Adeno-associated virus (AAV)-based gene therapies have emerged as the leading therapeutic strategy for XLRP by delivering functional copies of the RPGR gene directly to retinal cells. These approaches aim to slow or halt retinal degeneration while preserving visual function.

Growing Investment in Precision Ophthalmology: Significant investments from biotechnology companies, regulatory support through Orphan Drug Designation, Fast Track Designation, PRIME designation, RMAT designation, and increasing clinical trial activity are accelerating the development of disease-modifying therapies for inherited retinal diseases.

X-Linked Retinitis Pigmentosa (XLRP) Competitive Landscape

Several X-Linked Retinitis Pigmentosa therapies are currently under clinical development, including Botaretigene sparoparvovec (Johnson & Johnson Innovative Medicine/MeiraGTx), Laru-Zova (Beacon Therapeutics), and FT-002 (Frontera Therapeutics).

These investigational therapies utilize AAV-mediated gene replacement strategies designed to deliver functional RPGR genes to retinal photoreceptor cells. Their differentiated mechanisms aim to preserve retinal function, slow disease progression, and potentially provide long-term clinical benefits following a single administration.

Discover more about therapies set to grab major X-Linked Retinitis Pigmentosa market share @ X-Linked Retinitis Pigmentosa Treatment Landscape

Recent Developments in the X-Linked Retinitis Pigmentosa (XLRP) Market

• In December 2025, Beacon Therapeutics announced the treatment of the first patient in its LANDSCAPE clinical trial evaluating bilateral administration of Laru-Zova for patients with X-Linked Retinitis Pigmentosa.

• In July 2025, Beacon Therapeutics completed enrollment in the registrational Phase II/III VISTA trial evaluating Laru-Zova, with topline 12-month data expected during the second half of 2026.

• In May 2025, Johnson & Johnson Innovative Medicine reported that Botaretigene sparoparvovec (bota-vec) did not meet the primary endpoint in the Phase III LUMEOS clinical trial, although several patients demonstrated meaningful improvements in vision-guided mobility assessment (VMA).

• In September 2024, Frontera Therapeutics announced that FT-002 received US FDA clearance to initiate a Phase II clinical trial for X-Linked Retinitis Pigmentosa.

What is X-Linked Retinitis Pigmentosa (XLRP)?

X-Linked Retinitis Pigmentosa (XLRP) is a rare inherited retinal degenerative disorder primarily caused by mutations in the RPGR gene and, less frequently, the RP2 gene. The disease leads to progressive degeneration of retinal photoreceptors, resulting in night blindness, peripheral vision loss, progressive visual field constriction, and eventual central vision impairment. XLRP predominantly affects males, although female carriers may also experience varying degrees of visual impairment. Currently, there are no approved disease-modifying therapies for XLRP; however, multiple gene therapy candidates are advancing through clinical development with the goal of restoring functional RPGR expression and slowing disease progression.

X-Linked Retinitis Pigmentosa (XLRP) Epidemiology Segmentation

The X-Linked Retinitis Pigmentosa (XLRP) epidemiology section provides insights into the historical and current X-Linked Retinitis Pigmentosa patient pool and forecasted trends for the leading markets. The X-Linked Retinitis Pigmentosa market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

• Total Prevalent Cases of Retinitis Pigmentosa

• Type-specific (Syndromic and Non-syndromic) Cases of Retinitis Pigmentosa

• Prevalent Cases of X-Linked Retinitis Pigmentosa (Non-syndromic)

• Mutation-specific Cases of X-Linked Retinitis Pigmentosa (RPGR, RP2, and Others)

Scope of the X-Linked Retinitis Pigmentosa (XLRP) Market Report

• Therapeutic Assessment: X-Linked Retinitis Pigmentosa current marketed and emerging therapies

• X-Linked Retinitis Pigmentosa Market Dynamics: Key Market Forecast Assumptions of Emerging X-Linked Retinitis Pigmentosa Therapies and Market Outlook

• Key Companies: Beacon Therapeutics, Johnson & Johnson Innovative Medicine, MeiraGTx, Frontera Therapeutics, and others

• Key Therapies: Laru-Zova, Botaretigene sparoparvovec (Bota-vec), FT-002, Vitamin A, Lutein, Zeaxanthin, and others

• Competitive Intelligence Analysis: SWOT Analysis and Market Entry Strategies

• Unmet Needs, KOL’s Views, Analyst’s Views, X-Linked Retinitis Pigmentosa Market Access and Reimbursement

To know more about X-Linked Retinitis Pigmentosa companies working in the treatment market, visit @ X-Linked Retinitis Pigmentosa Clinical Trials and Therapeutic Assessment

Table of Contents

• X-Linked Retinitis Pigmentosa Market Report Introduction

• Executive Summary for X-Linked Retinitis Pigmentosa

• Key Events

• X-Linked Retinitis Pigmentosa Market Overview at a Glance

• Clinical Landscape Analysis

• Market Share (%) Distribution by Therapies

• Epidemiology and Market Forecast Methodology

• X-Linked Retinitis Pigmentosa Disease Background and Overview

• Signs and Symptoms

• Causes of X-Linked Retinitis Pigmentosa

• Classification of X-Linked Retinitis Pigmentosa

• Pathophysiology

• Diagnosis

• Diagnostic Tests

• Differential Diagnosis

• Diagnostic Guidelines

• Prognosis

• Treatment of X-Linked Retinitis Pigmentosa

• Future Treatment Modalities

• Treatment Guidelines

• Epidemiology and Patient Population

• Country-Specific Patient Population of X-Linked Retinitis Pigmentosa

• Patient Journey

• Emerging Drugs

• Key Competitors

• Botaretigene sparoparvovec (Johnson & Johnson Innovative Medicine/MeiraGTx)

• Laruparetigene zovaparvovec (Laru-Zova)

• FT-002

• X-Linked Retinitis Pigmentosa Market Analysis

• Market Outlook

• Conjoint Analysis

• Key Market Forecast Assumptions

• Pricing Trends

• Launch Year and Therapy Uptake

• Total Market Size of X-Linked Retinitis Pigmentosa in the 7MM

• Country-Wise X-Linked Retinitis Pigmentosa Market Analysis (2022–2036)

• Market Access and Reimbursement

• KOL Views

• SWOT Analysis

• X-Linked Retinitis Pigmentosa Unmet Needs

• X-Linked Retinitis Pigmentosa Appendix

• X-Linked Retinitis Pigmentosa Report Methodology

• DelveInsight Capabilities

• Disclaimer

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/